- Home
- HSII vs ABVX Comparison
HSII vs ABVX Comparison
Compare HSII & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- ABVX
- Stock Information
- Founded
- HSII 1953
- ABVX 2013
- Country
- HSII United States
- ABVX France
- Employees
- HSII N/A
- ABVX N/A
- Industry
- HSII Diversified Commercial Services
- ABVX
- Sector
- HSII Consumer Discretionary
- ABVX
- Exchange
- HSII Nasdaq
- ABVX Nasdaq
- Market Cap
- HSII 753.6M
- ABVX 722.3M
- IPO Year
- HSII 1999
- ABVX N/A
- Fundamental
- Price
- HSII $38.76
- ABVX $10.35
- Analyst Decision
- HSII Buy
- ABVX Strong Buy
- Analyst Count
- HSII 2
- ABVX 6
- Target Price
- HSII $38.50
- ABVX $36.50
- AVG Volume (30 Days)
- HSII 105.0K
- ABVX 167.4K
- Earning Date
- HSII 10-28-2024
- ABVX 09-09-2024
- Dividend Yield
- HSII 1.58%
- ABVX N/A
- EPS Growth
- HSII N/A
- ABVX N/A
- EPS
- HSII 1.84
- ABVX N/A
- Revenue
- HSII $1,060,145,000.00
- ABVX $9,676,417.00
- Revenue This Year
- HSII $5.95
- ABVX N/A
- Revenue Next Year
- HSII $2.94
- ABVX $1,541.09
- P/E Ratio
- HSII $20.65
- ABVX N/A
- Revenue Growth
- HSII 5.86
- ABVX 100.87
- 52 Week Low
- HSII $22.52
- ABVX $8.00
- 52 Week High
- HSII $41.94
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- HSII 59.19
- ABVX 48.24
- Support Level
- HSII $36.49
- ABVX $8.75
- Resistance Level
- HSII $37.59
- ABVX $9.97
- Average True Range (ATR)
- HSII 0.79
- ABVX 0.56
- MACD
- HSII 0.11
- ABVX 0.05
- Stochastic Oscillator
- HSII 91.90
- ABVX 54.61
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.